Established two decades ago, the essential tremor brain bank at Columbia has been instrumental in revealing the source and biology of a common but understudied neurodegenerative disorder.
Analysis of 1.6 million brain cells from older adults has captured the cellular changes that occur in Alzheimer’s early stages, revealing potential new targets and routes for prevention.
An international study shows as many as one-quarter of unresponsive patients with brain injuries have some level of awareness, a finding that could spur development of new treatments.
ADScreen, a speech-processing algorithm developed at Columbia Nursing, is now being tested in a clinical trial to see if it can help health care workers identify patients with Alzheimer's earlier.
Botanists are using pioneering technology—designed by Columbia neuroscientists to understand the human brain—to uncover electrical signals that help Venus flytraps ensnare prey.
A mechanism used by adult zebrafish to create new neurons in the brain is dormant in people; reawakening it might repair our brains and slow Alzheimer’s disease.
A study led by Columbia neurosurgeons has found that MRI-guided laser ablation is a viable treatment that can provide lasting seizure control for people with drug-resistant temporal lobe epilepsy.
A new study in mice shows that new neurons created in the brain during adulthood are needed to maintain working memory—the temporary “sticky notes” of the brain.
Many researchers believe that the neurodegenerative disorder gets started in the gut. Columbia research now suggests that an autoimmune reaction may be driving those early events.
Columbia researchers have identified brain circuits that, when injured, make conscious patients with acute brain injury appear unresponsive, a phenomenon known as hidden consciousness.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.